These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1362 related items for PubMed ID: 27079874

  • 1. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A, Sjouke B, Passard M, Prampart-Fauvet S, Guédon A, Croyal M, Dallinga-Thie G, Peter J, Blom D, Ciccarese M, Cefalù AB, Pisciotta L, Santos RD, Averna M, Raal F, Pintus P, Cossu M, Hovingh K, Lambert G.
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [Abstract] [Full Text] [Related]

  • 2. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J, Poitiers F, Paehler T, Brunet A, DiCioccio AT, Cannon CP, Surks HK, Pinquier JL, Hanotin C, Sasiela WJ.
    J Am Heart Assoc; 2016 Jun 10; 5(6):. PubMed ID: 27287699
    [Abstract] [Full Text] [Related]

  • 3. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G.
    Arterioscler Thromb Vasc Biol; 2018 Mar 10; 38(3):592-598. PubMed ID: 29284604
    [Abstract] [Full Text] [Related]

  • 4. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA, Elshourbagy NA, Mousa SA.
    Pharmacol Ther; 2016 Aug 10; 164():183-94. PubMed ID: 27133571
    [Abstract] [Full Text] [Related]

  • 5. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K.
    Curr Pharm Des; 2017 Aug 10; 23(10):1495-1499. PubMed ID: 28155622
    [Abstract] [Full Text] [Related]

  • 6. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S, Robertson DG, Joh T, Wan H, Riel T, Forgues P, Baum CM, Garzone PD, Gumbiner B.
    Cardiovasc Ther; 2018 Feb 10; 36(1):. PubMed ID: 29057618
    [Abstract] [Full Text] [Related]

  • 7. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
    Schmitz J, Gouni-Berthold I.
    Curr Pharm Des; 2017 Feb 10; 23(10):1484-1494. PubMed ID: 28137217
    [Abstract] [Full Text] [Related]

  • 8. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
    Gumbiner B, Joh T, Liang H, Wan H, Levisetti M, Vana AM, Shelton DL, Forgues P, Billotte S, Pons J, Baum CM, Garzone PD.
    Cardiovasc Ther; 2018 Feb 10; 36(1):. PubMed ID: 29078037
    [Abstract] [Full Text] [Related]

  • 9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct 10; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN, Serra C.
    Pharmacotherapy; 2015 Aug 10; 35(8):771-9. PubMed ID: 26256279
    [Abstract] [Full Text] [Related]

  • 11. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
    Koren MJ, Kereiakes D, Pourfarzib R, Winegar D, Banerjee P, Hamon S, Hanotin C, McKenney JM.
    J Am Heart Assoc; 2015 Nov 19; 4(11):. PubMed ID: 26586732
    [Abstract] [Full Text] [Related]

  • 12. A case of autosomal recessive hypercholesterolemia responsive to proprotein convertase subtilisin/kexin 9 inhibition.
    Fahy EF, McCarthy E, Steinhagen-Thiessen E, Vaughan CJ.
    J Clin Lipidol; 2017 Nov 19; 11(1):287-288. PubMed ID: 28391897
    [Abstract] [Full Text] [Related]

  • 13. A new variant (c.1A>G) in LDLRAP1 causing autosomal recessive hypercholesterolemia: Characterization of the defect and response to PCSK9 inhibition.
    Rodríguez-Jiménez C, Gómez-Coronado D, Frías Vargas M, Cerrato F, Lahoz C, Saban-Ruiz J, González-Nieto D, Lasunción MA, Mostaza JM, Rodríguez-Nóvoa S.
    Atherosclerosis; 2019 May 19; 284():223-229. PubMed ID: 30777337
    [Abstract] [Full Text] [Related]

  • 14. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V, Katsiki N, Makrygiannis S, Mavrogieni S, Karampetsou N, Manolis A, Melidonis A, Mikhailidis DP, Kolovou GD.
    J Cardiovasc Pharmacol Ther; 2021 Jan 19; 26(1):51-58. PubMed ID: 32729335
    [Abstract] [Full Text] [Related]

  • 15. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F, Dal Pino B, Bigazzi F, Ripoli A, Passino C, Gabutti A, Pasanisi EM, Petersen C, Valleggi A, Todiere G, Barison A, Giannoni A, Panchetti L, Becherini F, Pianelli M, Luciani R, Sampietro T.
    Eur J Prev Cardiol; 2017 Sep 19; 24(14):1528-1531. PubMed ID: 28555526
    [Abstract] [Full Text] [Related]

  • 16. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 19; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
    Gouni-Berthold I.
    Atheroscler Suppl; 2017 Nov 19; 30():9-18. PubMed ID: 29096867
    [Abstract] [Full Text] [Related]

  • 18. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.
    Tavori H, Melone M, Rashid S.
    Expert Rev Cardiovasc Ther; 2014 Oct 19; 12(10):1137-44. PubMed ID: 25244623
    [Abstract] [Full Text] [Related]

  • 19. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG, Prat A, Pirillo A, Catapano AL, Norata GD.
    Cardiovasc Res; 2019 Mar 01; 115(3):510-518. PubMed ID: 30629143
    [Abstract] [Full Text] [Related]

  • 20. The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.
    Athyros VG, Tziomalos K, Doumas M, Sfikas G, Karagiannis A.
    Curr Pharm Des; 2017 Mar 01; 23(10):1477-1483. PubMed ID: 28128061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.